A Non-Interventional, Observational Phase IV Study to Evaluate Safety of Rituximab (Mabthera®) in Combination With Chemotherapy in Patients Treated With CD20+ Β Chronic Lymphocytic Leukemia
Phase of Trial: Phase IV
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Rituximab (Primary) ; Antineoplastics
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Acronyms CaLLypso
- Sponsors Roche
- 01 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Jan 2015 Planned End Date changed from 1 Oct 2015 to 1 Nov 2015, as reported by ClinicalTrials.gov.
- 26 Jan 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Nov 2015, as reported by ClinicalTrials.gov.